{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Myelogenous+Leukemia+-+Chronic+Phase&page=11", "query": { "condition": "Chronic Myelogenous Leukemia - Chronic Phase", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 949, "total_pages": 95, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Myelogenous+Leukemia+-+Chronic+Phase&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Myelogenous+Leukemia+-+Chronic+Phase&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T23:07:13.181Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01175785", "title": "Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Previously Treated Myelodysplastic Syndromes", "Refractory Anemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Relapsing Chronic Myelogenous Leukemia", "Secondary Myelodysplastic Syndromes" ], "interventions": [ { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "ex vivo-expanded cord blood progenitor cell infusion", "type": "BIOLOGICAL" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "Nohla Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "45 Years", "sex": "ALL", "summary": "6 Months to 45 Years" }, "enrollment_count": 15, "start_date": "2010-08", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-10-13T23:07:13.181Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01175785" }, { "nct_id": "NCT04372433", "title": "IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML With Monocytic Differentiation", "CMML" ], "interventions": [ { "name": "IO-202", "type": "BIOLOGICAL" }, { "name": "IO-202 and Azacitidine", "type": "BIOLOGICAL" }, { "name": "IO-202 and Azacitidine + Venetoclax", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Immune-Onc Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2020-09-14", "completion_date": "2025-01-31", "has_results": false, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-10-13T23:07:13.181Z", "location_count": 14, "location_summary": "Davis, California • Duarte, California • Irvine, California + 11 more", "locations": [ { "city": "Davis", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04372433" }, { "nct_id": "NCT00298987", "title": "A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Chronic", "Leukemia, Lymphocytic, Acute, L2" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2006-02", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2010-02-08", "last_synced_at": "2026-10-13T23:07:13.181Z", "location_count": 30, "location_summary": "Corona, California • Aurora, Colorado • Colorado Springs, Colorado + 27 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Waterford", "state": "Connecticut" }, { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00298987" }, { "nct_id": "NCT01490983", "title": "Telemonitoring Study - for Chronic Myeloid Leukemia (CML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "no access to eMedonline", "type": "BEHAVIORAL" }, { "name": "eMedonline access", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Rex Cancer Center, Raleigh, NC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2009-04", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2018-08-13", "last_synced_at": "2026-10-13T23:07:13.181Z", "location_count": 3, "location_summary": "Chapel Hill, North Carolina • Raleigh, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01490983" }, { "nct_id": "NCT03326310", "title": "Selumetinib and Azacitidine in High Risk Chronic Blood Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloid Leukemia", "Myelofibroses" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-09-04", "completion_date": "2027-09-04", "has_results": false, "last_update_posted_date": "2025-12-29", "last_synced_at": "2026-10-13T23:07:13.181Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03326310" }, { "nct_id": "NCT00023920", "title": "Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "idarubicin", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2001-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-23", "last_synced_at": "2026-10-13T23:07:13.181Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023920" }, { "nct_id": "NCT00569179", "title": "A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Acute", "Leukemia, Lymphoid", "Myelodysplastic Syndromes", "Leukemia, Myelogenous, Chronic" ], "interventions": [ { "name": "CliniMACS CD34 Reagent System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1, "start_date": "2007-08", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2015-08-31", "last_synced_at": "2026-10-13T23:07:13.181Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00569179" }, { "nct_id": "NCT00105001", "title": "Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Previously Treated Myelodysplastic Syndrome", "Refractory Chronic Lymphocytic Leukemia", "Refractory Plasma Cell Myeloma", "Waldenstrom Macroglobulinemia", "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Burkitt Lymphoma", "Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Lymphoma", "Childhood Myelodysplastic Syndrome", "Stage II Contiguous Adult Burkitt Lymphoma", "Stage II Contiguous Adult Diffuse Large Cell Lymphoma", "Stage II Contiguous Adult Diffuse Mixed Cell Lymphoma", "Stage II Contiguous Adult Diffuse Small Cleaved Cell Lymphoma", "Stage II Adult Contiguous Immunoblastic Lymphoma", "Stage II Contiguous Adult Lymphoblastic Lymphoma", "Stage II Grade 1 Contiguous Follicular Lymphoma", "Stage II Grade 2 Contiguous Follicular Lymphoma", "Stage II Grade 3 Contiguous Follicular Lymphoma", "Stage II Contiguous Mantle Cell Lymphoma", "Stage II Non-Contiguous Adult Burkitt Lymphoma", "Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma", "Stage II Non-Contiguous Adult Diffuse Mixed Cell Lymphoma", "Stage II Non-Contiguous Adult Diffuse Small Cleaved Cell Lymphoma", "Stage II Adult Non-Contiguous Immunoblastic Lymphoma", "Stage II Non-Contiguous Adult Lymphoblastic Lymphoma", "Stage II Grade 1 Non-Contiguous Follicular Lymphoma", "Stage II Grade 2 Non-Contiguous Follicular Lymphoma", "Stage II Grade 3 Non-Contiguous Follicular Lymphoma", "Stage II Non-Contiguous Mantle Cell Lymphoma", "Stage II Small Lymphocytic Lymphoma", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Burkitt Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Recurrent Childhood Hodgkin Lymphoma", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Secondary Myelodysplastic Syndrome", "Stage I Adult Burkitt Lymphoma", "Stage I Adult Diffuse Large Cell Lymphoma", "Stage I Adult Diffuse Mixed Cell Lymphoma", "Stage I Adult Immunoblastic Lymphoma", "Stage I Adult Lymphoblastic Lymphoma", "Stage I Childhood Anaplastic Large Cell Lymphoma", "Stage I Childhood Large Cell Lymphoma", "Stage I Childhood Lymphoblastic Lymphoma", "Stage I Childhood Burkitt Lymphoma", "Stage I Grade 1 Follicular Lymphoma", "Stage I Grade 2 Follicular Lymphoma", "Stage I Grade 3 Follicular Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage I Marginal Zone Lymphoma", "Stage I Small Lymphocytic Lymphoma", "Stage II Childhood Anaplastic Large Cell Lymphoma", "Stage II Childhood Lymphoblastic Lymphoma", "Stage II Childhood Burkitt Lymphoma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Immunoblastic Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Childhood Anaplastic Large Cell Lymphoma", "Stage III Childhood Large Cell Lymphoma", "Stage III Childhood Lymphoblastic Lymphoma", "Stage III Childhood Burkitt Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Immunoblastic Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Childhood Anaplastic Large Cell Lymphoma", "Stage IV Childhood Large Cell Lymphoma", "Stage IV Childhood Lymphoblastic Lymphoma", "Stage IV Childhood Burkitt Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 210, "start_date": "2004-11", "completion_date": "2015-05-08", "has_results": true, "last_update_posted_date": "2019-10-30", "last_synced_at": "2026-10-13T23:07:13.181Z", "location_count": 7, "location_summary": "Denver, Colorado • Atlanta, Georgia • Salt Lake City, Utah + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00105001" }, { "nct_id": "NCT00278330", "title": "Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Blastic Phase Chronic Myelogenous Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Anemia With Excess Blasts", "Relapsing Chronic Myelogenous Leukemia", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "alvocidib", "type": "DRUG" }, { "name": "vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2006-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-02", "last_synced_at": "2026-10-13T23:07:13.181Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00278330" }, { "nct_id": "NCT00004245", "title": "Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "sodium salicylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-18", "last_synced_at": "2026-10-13T23:07:13.181Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004245" } ] }